TPLS yields 4.49% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, TPLS + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TPLS + PFE for your $10,000?
TPLS builds a diversified fixed-income portfolio focused on total return through both income and capital appreciation. Investments include corporate bonds, government securities, MBS, ABS, and bank loans. The fund is flexible, allowing investments in securities of any credit quality and maturity. While it primarily invests in domestic issuers, it may also hold foreign debt, including obligations denominated in non-U.S. currencies, with foreign currency exposure limited to 25%. Additionally, the fund may allocate up to 25% of its assets to high-yield bonds, and exposure to emerging markets is capped at 15%. Security selection relies on fundamental research, which involves proprietary and third-party analysis to evaluate credit quality, economic trends, and valuation. Derivatives may also be used to enhance the portfolio or hedge risks. Positions may be sold to adjust duration, mitigate risk, or take advantage of more attractive opportunities.
Full TPLS Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.